[1] MIGUEL A. ORTEGA . Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-Dependent kinases inhibitors[J]. Bioorganic & Medicinal Chemistry, 2002, 10 7: Pages 2177-2184. DOI:
10.1016/s0968-0896(02)00069-x[2] SHAOYONG CHEN. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103 43: 15969-15974. DOI:
10.1073/pnas.0604193103[3] TRI K NGUYEN Steven G. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism.[J]. Molecular Cancer Therapeutics, 2014: 662-674. DOI:
10.1158/1535-7163.mct-13-0714[4] SUPACHAI TOPANURAK. High NaCl- and urea-induced posttranslational modifications that increase glycerophosphocholine by inhibiting GDPD5 phosphodiesterase.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2013: 7482-7487. DOI:
10.1073/pnas.1305220110